Showing 1 - 2 results of 2 for search 'Nahla A Azzam', query time: 0.01s Refine Results
  1. 1
    Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

    Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective. by Nimer S Alkhatib, Abdulaali R Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A Azzam, Mahmoud H Mosli, Amal M Badawoud, Majed S Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective

    Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective by Nimer S. Alkhatib, Abdulaali R. Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H. Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A. Azzam, Mahmoud H. Mosli, Amal M. Badawoud, Majed S. Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: